Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - September 2014

17 September 2014, Updated 23 September 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 8-11 September 2014. Topics discussed at the meeting:

  • PRAC concludes review of Valdoxan/Thymanax (agomelatine).
  • Two years of focus on patient safety.
  • One month left to respond to the consultation on public hearings.

Read PRAC's monthly report from the meeting 8-11 September 2014

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.